Q: What is Ngenla used for?

Ngenla is used to treat pediatric growth hormone deficiency.

Q: How does Ngenla work?

Mechanism of Action Ngenla belongs to a class of medications known as growth hormones. It is a laboratory-made version of the growth hormone naturally produced by the pituitary gland. In children with growth hormone deficiency, the body does not produce enough of this hormone to support normal physical development. Ngenla works by mimicking the effects of natural growth hormone in the body through the following process: Receptor Binding: Once injected, the medication binds to specific growth hormone receptors on the surface of cells. Stimulating Growth Factors: This binding triggers the release of insulin-like growth factor-1 (IGF-1), a protein that is essential for childhood growth. Promoting Development: Growth hormone and IGF-1 work together to signal the bones and other tissues to grow, helping the child increase their height and reach developmental milestones. Ngenla is specifically engineered to be long-acting. It remains active in the bloodstream for an extended period, which allows it to provide a steady supply of the hormone with one injection per week, rather than the daily injections required by some other growth hormone treatments.

Q: What are the active ingredients in Ngenla?

The active ingredient in Ngenla is somatrogon .

Q: What are the side effects of Ngenla?

Common side effects of Ngenla may include: injection site reactions joint pain headache Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ngenla?

Ngenla belongs to the growth hormone drug class.

Q: What is the dosage of Ngenla and how do I take it?

Administration Ngenla is injected subcutaneously (under the skin) using a prefilled pen. It is typically administered once a week on the same day each week. Common injection sites include the abdomen, thighs, or buttocks. It is important to rotate the injection site with each dose to help prevent skin irritation or changes in the fatty tissue under the skin. Before administration, the medication should be removed from the refrigerator and allowed to reach room temperature. The solution should be clear and colorless to slightly yellow; do not use the medication if it is cloudy, discolored, or contains visible particles. Always use a new, sterile needle for every injection and follow proper disposal procedures for used needles. Missed Dose If a dose is missed, it should be taken as soon as possible, provided it is within a few days of the scheduled day. If too much time has passed since the missed dose, skip it and wait until the next regularly scheduled day to resume the treatment. Do not administer a double dose to make up for a missed one.

Q: Is Ngenla safe during pregnancy and breastfeeding?

Pregnancy It is currently unknown whether Ngenla can cause harm to an unborn baby. Clinical trials have not specifically studied the use of this medication in pregnant individuals. If a patient becomes pregnant or plans to become pregnant while using Ngenla, they should consult their healthcare provider to discuss the potential risks and benefits of continuing treatment. Breastfeeding It is not known if Ngenla passes into breast milk or if it could affect a nursing child. Because the effects on a breastfeeding infant are uncertain, it is important for patients to talk with their doctor about the risks and benefits of breastfeeding while receiving this medication.

Q: What forms and strengths does Ngenla come in?

Available Forms Ngenla is supplied as a sterile solution for injection. It is available in the following delivery format: Prefilled Pen: A single-patient-use, disposable injection device containing a clear to slightly yellow liquid solution. The medication is designed for subcutaneous injection once per week. The prefilled pen is a multi-dose device intended for use by a single patient. Once the pen is empty or has reached the end of its use period after being opened, it must be disposed of according to safety guidelines.

Q: What is the FDA approval status of Ngenla?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Ngenla on June 27, 2023. It is classified as a human growth hormone analog. The medication is specifically indicated for the treatment of pediatric patients 3 years of age and older who have growth failure due to an inadequate secretion of endogenous growth hormone. Regulatory History Ngenla was developed as a long-acting alternative to daily growth hormone injections. Its approval was based on clinical evidence demonstrating its safety and efficacy in promoting growth in children with growth hormone deficiency. The FDA approval provides a once-weekly subcutaneous injection option for this patient population. Safety and Monitoring At the time of approval, the FDA did not require a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) for Ngenla. As with other growth hormone products, regulatory authorities monitor the drug for potential side effects such as injection site reactions, headaches, and joint pain. Healthcare providers are expected to monitor patients regularly for growth response and potential adverse events during treatment.

Question 1

What is Ngenla?

Accepted Answer

Ngenla is a prescription medication that acts as a long-acting analog of human growth hormone. It is developed using recombinant DNA technology to mimic the effects of the growth hormone naturally produced by the pituitary gland.

This therapy works by binding to specific receptors in the body to promote growth and various metabolic processes. It serves as a replacement for natural growth hormone when the body does not produce enough of its own.

Question 2

What is Ngenla used for?

Accepted Answer

Ngenla is used to treat pediatric growth hormone deficiency.

Question 3

How does Ngenla work?

Accepted Answer

Mechanism of Action

Ngenla belongs to a class of medications known as growth hormones. It is a laboratory-made version of the growth hormone naturally produced by the pituitary gland. In children with growth hormone deficiency, the body does not produce enough of this hormone to support normal physical development.

Ngenla works by mimicking the effects of natural growth hormone in the body through the following process:

Receptor Binding: Once injected, the medication binds to specific growth hormone receptors on the surface of cells.
Stimulating Growth Factors: This binding triggers the release of insulin-like growth factor-1 (IGF-1), a protein that is essential for childhood growth.
Promoting Development: Growth hormone and IGF-1 work together to signal the bones and other tissues to grow, helping the child increase their height and reach developmental milestones.

Ngenla is specifically engineered to be long-acting. It remains active in the bloodstream for an extended period, which allows it to provide a steady supply of the hormone with one injection per week, rather than the daily injections required by some other growth hormone treatments.

Question 4

What are the active ingredients in Ngenla?

Accepted Answer

The active ingredient in Ngenla is somatrogon.

Question 5

What are the side effects of Ngenla?

Accepted Answer

Common side effects of Ngenla may include:

injection site reactions
joint pain
headache

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ngenla?

Accepted Answer

Ngenla belongs to the growth hormone drug class.

Question 7

What is the dosage of Ngenla and how do I take it?

Accepted Answer

Administration

Ngenla is injected subcutaneously (under the skin) using a prefilled pen. It is typically administered once a week on the same day each week. Common injection sites include the abdomen, thighs, or buttocks. It is important to rotate the injection site with each dose to help prevent skin irritation or changes in the fatty tissue under the skin.

Before administration, the medication should be removed from the refrigerator and allowed to reach room temperature. The solution should be clear and colorless to slightly yellow; do not use the medication if it is cloudy, discolored, or contains visible particles. Always use a new, sterile needle for every injection and follow proper disposal procedures for used needles.

Missed Dose

If a dose is missed, it should be taken as soon as possible, provided it is within a few days of the scheduled day. If too much time has passed since the missed dose, skip it and wait until the next regularly scheduled day to resume the treatment. Do not administer a double dose to make up for a missed one.

Question 8

Is Ngenla safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is currently unknown whether Ngenla can cause harm to an unborn baby. Clinical trials have not specifically studied the use of this medication in pregnant individuals. If a patient becomes pregnant or plans to become pregnant while using Ngenla, they should consult their healthcare provider to discuss the potential risks and benefits of continuing treatment.

Breastfeeding

It is not known if Ngenla passes into breast milk or if it could affect a nursing child. Because the effects on a breastfeeding infant are uncertain, it is important for patients to talk with their doctor about the risks and benefits of breastfeeding while receiving this medication.

Question 9

What forms and strengths does Ngenla come in?

Accepted Answer

Available Forms

Ngenla is supplied as a sterile solution for injection. It is available in the following delivery format:

Prefilled Pen: A single-patient-use, disposable injection device containing a clear to slightly yellow liquid solution.

The medication is designed for subcutaneous injection once per week. The prefilled pen is a multi-dose device intended for use by a single patient. Once the pen is empty or has reached the end of its use period after being opened, it must be disposed of according to safety guidelines.

Question 10

What is the FDA approval status of Ngenla?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Ngenla on June 27, 2023. It is classified as a human growth hormone analog. The medication is specifically indicated for the treatment of pediatric patients 3 years of age and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

Regulatory History

Ngenla was developed as a long-acting alternative to daily growth hormone injections. Its approval was based on clinical evidence demonstrating its safety and efficacy in promoting growth in children with growth hormone deficiency. The FDA approval provides a once-weekly subcutaneous injection option for this patient population.

Safety and Monitoring

At the time of approval, the FDA did not require a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) for Ngenla. As with other growth hormone products, regulatory authorities monitor the drug for potential side effects such as injection site reactions, headaches, and joint pain. Healthcare providers are expected to monitor patients regularly for growth response and potential adverse events during treatment.

Question 11

What should I know about Ngenla and cost?

Accepted Answer

Factors Affecting Cost

The actual price paid for Ngenla depends on several variables. These include the type of insurance plan, the specific pharmacy dispensing the medication, and the dosage required based on the patient's weight.

Insurance and Prior Authorization

Many insurance companies require prior authorization for Ngenla. This means the healthcare provider must submit documentation explaining why the medication is medically necessary before the insurance company will agree to cover the cost. Out-of-pocket costs like copays and deductibles will vary by plan.

Financial Assistance

Financial assistance may be available for eligible patients to help manage the cost of Ngenla:

Copay Cards: The manufacturer may offer savings cards for patients with commercial insurance to reduce out-of-pocket expenses.
Patient Assistance Programs: For those without insurance or whose insurance does not cover the drug, programs may provide the medication at a reduced cost or for free based on financial need.

Because Ngenla is a specialty medication, it is typically not available at all retail pharmacies. Patients may need to use a specialty pharmacy designated by their insurance provider.

Ngenla

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ngenla

Hospitals.net Disclosure